Uric acid in chronic heart failure: Marker or therapeutic target?

Archives of Medical Science

Volumn 4, Issue 3, 2008, Pages 226-228

  Doehner, Wolfram ^a   Anker, Stefan D ^a   Filippatos, Gerasimos S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

OXIPURINOL; REACTIVE OXYGEN METABOLITE; URIC ACID; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; DISEASE MARKER; DRUG TARGETING; ENZYME ACTIVITY; HEART FAILURE; HUMAN; HYPERURICEMIA; IMMUNE RESPONSE; NONHUMAN; NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS;

EID: 58549084214     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Patel PD, Arora RR. Uric acid and xanthine oxidase: perspectives in chronic heart failure. Arch Med Sci 2008; 4: 219-25.
2. McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 1968; 243: 5753-60.
3. Maxwell SR, Thomason H, Sandler D, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27: 484-90.
4. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073-8.
5. Doehner W, von Haehling S, Anker SD. Uric acid in CHF: marker or player in a metabolic disease? Int J Cardiol 2007; 115: 156-8.
6. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 1981; 25: 67-82.
7. Sarnesto A, Linder N, Raivio KO. Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Invest 1996; 74: 48-56.
8. Tubaro E, Lotti B, Cavallo G, Croce C, Borelli G. Liver xanthine oxidase increase in mice in three patholgoical models. A possible defence mechanism. Biochem Pharmacol 1980; 29: 1939-43.
9. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-7.
10. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
11. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-82.
12. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-16.
13. Hare JM, Mangal B, Brown J, et al.; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51: 2301-9.
14. Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 2005; 91: 707-9.